“Timothy Yap, MBBS, PhD, FRCP, The University of Texas MD Anderson Cancer Center, Houston, TX discusses the A1 results from the Phase I study of M1744 (NCT04170153), a potent, selective, orally administered ATR inhibitor which exerts antitumour activity in preclinical models. These early data show M1774 monotherapy in patients with advanced solid tumours is generally well-tolerated, up to the established maximum tolerated dose (and recommended dose) of 180mg per day. M1774 is continuing investigation in a biomarker-selected population in combination with niraparib. This interview took place at the European Society for Medical Oncology (ESMO) 2022 Congress in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
